MedPath

FDA Approves BridgeBio's Attruby (acoramidis) for ATTR-CM

• The FDA has approved Attruby (acoramidis) from BridgeBio, marking the first new treatment in over five years for transthyretin amyloid cardiomyopathy (ATTR-CM). • ATTR-CM, affecting over 400,000 globally, results from misfolded protein deposits in the heart, leading to impaired function and, without treatment, death within five years of diagnosis. • Attruby aims to stabilize transthyretin, preventing misfolding and subsequent amyloid formation, offering a new therapeutic option for both genetic and age-related ATTR-CM. • This approval signifies BridgeBio's first major commercial product, addressing a critical unmet need in the treatment of this progressive and life-threatening heart condition.

The Food and Drug Administration (FDA) has approved BridgeBio's Attruby (acoramidis) for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). This approval marks a significant milestone as the first new treatment option for this progressive heart disease in over five years.
ATTR-CM is a condition characterized by the misfolding and aggregation of transthyretin protein, leading to amyloid deposits in the heart. These deposits impair heart function, and without treatment, most patients succumb to the disease within five years of diagnosis. The disease affects an estimated 400,000 people worldwide and can arise from genetic mutations or aging.
Acoramidis, the active ingredient in Attruby, is designed to stabilize the transthyretin protein, preventing its misfolding and subsequent amyloid formation. By addressing the underlying cause of ATTR-CM, Attruby offers a potential disease-modifying approach to treatment.
This approval represents BridgeBio's first major commercial product, addressing a critical unmet need in the treatment of ATTR-CM. The availability of Attruby provides a new therapeutic option for patients suffering from this debilitating and life-threatening condition.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Approves BridgeBio's Attruby (acoramidis) for ATTR-CM

The FDA has approved Attruby (acoramidis) by BridgeBio Pharma for treating transthyretin amyloid cardiomyopathy (ATTR-CM) in adults, marking a significant advancement in cardiac care.
Attruby, an orally administered TTR stabilizer, is designed to reduce cardiovascular death and cardiovascular-related hospitalization by targeting the destabilization of the TTR tetramer.

FDA Approves Attruby (Acoramidis) for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

The FDA has approved Attruby (acoramidis) for treating transthyretin amyloid cardiomyopathy (ATTR-CM), offering a new hope for patients with this rare heart condition.
Attruby, a TTR stabilizer, demonstrated significant reduction in cardiovascular death and hospitalization in the ATTRibute-CM Phase 3 trial.

FDA Approves BridgeBio's Attruby (acoramidis) for Transthyretin Amyloid Cardiomyopathy

The FDA has approved BridgeBio's Attruby (acoramidis) for adults with transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and life-threatening heart condition.
Attruby is the first and only approved treatment that specifies near-complete stabilization of transthyretin (TTR), addressing the root cause of ATTR-CM.

FDA Approves BridgeBio's Attruby (acoramidis) for Transthyretin Amyloid Cardiomyopathy

The FDA has approved BridgeBio Pharma's Attruby (acoramidis) for treating transthyretin amyloid cardiomyopathy (ATTR-CM) in adults, marking a significant advancement in cardiac care.
Attruby is the first approved therapy with a label indicating near-complete transthyretin (TTR) stabilization, aiming to reduce cardiovascular deaths and hospitalizations associated with ATTR-CM.

FDA Approves BridgeBio's Attruby (acoramidis) for ATTR-CM Treatment

The FDA has approved BridgeBio Pharma's Attruby (acoramidis) for treating transthyretin amyloid cardiomyopathy (ATTR-CM) in adults, marking a significant advancement in cardiac care.
Attruby, an oral transthyretin (TTR) stabilizer, is the first approved product with a label specifying near-complete TTR stabilization, reducing cardiovascular deaths and hospitalizations.

FDA Approves BridgeBio's Acoramidis (ATTRUBY) for Transthyretin Amyloid Cardiomyopathy

The FDA has approved acoramidis (ATTRUBY), an oral transthyretin stabilizer, for treating transthyretin amyloid cardiomyopathy (ATTR-CM) in adults, aiming to reduce cardiovascular death and hospitalization.
Approval was based on the Phase 3 ATTRibute-CM study, which demonstrated significant reductions in mortality and cardiovascular hospitalizations, along with improved patient quality of life.

FDA Approves BridgeBio's Attruby for Transthyretin Amyloid Cardiomyopathy

The FDA has approved BridgeBio's Attruby (acoramidis) for transthyretin amyloid cardiomyopathy, offering a new treatment option.
Attruby demonstrated improved survival, reduced hospitalization, and enhanced quality of life in clinical trials compared to placebo.

FDA Approves BridgeBio's Attruby for ATTR-CM, Reducing Cardiovascular Death and Hospitalization

The FDA has approved Attruby (acoramidis), an oral TTR stabilizer developed by BridgeBio, for treating adults with ATTR-CM.
Attruby demonstrated a significant reduction in cardiovascular death and cardiovascular-related hospitalizations in the Phase 3 ATTRibute-CM study.

BridgeBio's Attruby Approved for ATTR-CM, Setting Up Competition with Pfizer's Tafamidis

The FDA has approved BridgeBio's Attruby (acoramidis) for transthyretin amyloid cardiomyopathy (ATTR-CM), offering a new treatment option for this progressive disease.
Attruby demonstrated a statistically significant improvement in a composite endpoint of cardiovascular death and hospitalization in a Phase 3 trial.

BridgeBio's Attruby Receives FDA Approval for ATTR-CM Treatment

The FDA has approved BridgeBio's Attruby (acoramidis) for treating adults with transthyretin amyloid cardiomyopathy (ATTR-CM), marking a significant milestone for the company.
Attruby is the first and only approved product with a label specifying near-complete stabilization of transthyretin, demonstrating benefits on cardiovascular outcomes.

Reference News

[1]
BridgeBio wins FDA approval for heart disease drug - STAT News
statnews.com · Nov 23, 2024

FDA approves BridgeBio's Attruby (acoramidis) for transthyretin amyloid cardiomyopathy (ATTR-CM), affecting over 400,000...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy